Abstract: The present disclosure provides compositions and methods of treating Breast Cancer. Disclosed is a nanoparticle paired to at least one of W genetic materials that suppress key regulators of fat synthesis (e.g. Rev-erb) to cause a predefined target cell types apoptosis or X predefined targeting moieties that cause predefined target cell types apoptosis and correspond to Y predefined target parameters associated with Z predefined target cell types in connection with treatment of at least one of the following breast cancer, glioblastoma, head and neck cancer, pancreatic cancer, lung cancer, cancer of the nervous system, gastrointestinal cancer, prostate cancer, ovarian cancer, kidney cancer, retina, cancer, skin cancer, liver cancer, genital.
Type:
Application
Filed:
December 22, 2012
Publication date:
December 12, 2013
Applicant:
NNANOAXIS, LLC
Inventors:
Krishnan Chakravarthy, Robert Spengler, Tracey Ignatowski, Siddhartha Kamisetti
Abstract: Multiplexed assays are disclosed for detection of duster differentiation 4 (CD4) glycoprotein expressed on the cell surface of I-helper cells, monocytes, macrophages, and dendritic cells; cluster differentiation 25 (CD25), a type transmembrane protein present on activated T-cells, activated B-cells, thymocytes, myeloid precursors, and oligodendrocytes; and Forkhead box P3 (FOXP3), an intracellular protein involved in immune system responses in cell cultures, tissues samples, humans, and biological samples. The multiplexed assays can be used to detect 1r-cells, activated I-cells, and other similar cell types (e.g. natural T regulatory cells, adaptive/induced T regulatory T cells). The multiplexed assays employ quantum dots of various shapes, types, compositions, coatings, sizes, ligands and other such characteristics.
Abstract: The present disclosure provides compositions and methods of treating Alzheimers Disease. In an aspect, a nanoparticle is paired to one or more genetic materials that regulates inflammation in a microenvironment. Such nanoparticles can be used to target predefined target cell types in connection with treatment of at least one of the following Alzheimer's disease, Pick's disease, Lewy Body disease, or Idiopathic dementia.
Type:
Application
Filed:
June 8, 2012
Publication date:
December 13, 2012
Applicant:
NNANOAXIS, LLC
Inventors:
Krishnan Chakravarthy, Robert Spengler, Tracey Ignatowski, Siddhartha Venkata Kamisetti